Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Dual-acting peptide tackles triglycerides

  1. Sarah Crunkhorn
    View author publications

    You can also search for this author in PubMed  Google Scholar

Hypertriglyceridaemia (HTG) is a causal risk factor for cardiovascular disease, and in patients with familial hyperchylomicronaemia (FC), HTG often leads to acute pancreatitis. Writing in Science Translational Medicine, Wolska, Remaley, Devalaraja and colleagues report the development of a dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide, which rapidly lowers plasma triglyceride (TG) levels in mouse models.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 168 (2020)

doi: https://doi.org/10.1038/d41573-020-00017-z

References

  1. Wolska, A. et al. A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci. Transl Med. 12, eaaw7905 (2020)

    Article  PubMed  Google Scholar 

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links